In this episode of The Downsized, Christopher Durham takes a deep look at the 15 most important new obesity medications currently in development. Some could reach patients within the next year. Others are showing weight loss results approaching 30% in clinical trials. There are new weekly injections, monthly injections, oral medications, amylin-based therapies, triple agonists, and treatments specifically being developed for people living with obesity and related conditions like MASH (fatty liver disease). Christopher breaks down the science, the clinical trial results, the FDA timelines, and what each medication could mean for real patients trying to treat the disease of obesity.Featured medications include:• CagriSema• Retatrutide• Survodutide• MariTide• VK2735• Mazdutide• Amycretin• Petrelintide• Eloralintide• PF-3944• Pemvidutide• And more. The future of obesity treatment is changing rapidly. The next five years could bring more new obesity medications than the previous two decades combined. But the biggest question remains: Will patients actually be able to afford them? About The Downsized Christopher and Laraine Durham have lost more than 150 pounds using GLP-1 medications and share their experiences as patients treating the disease of obesity. The Downsized covers obesity medicine, GLP-1 medications, weight loss research, healthcare policy, patient advocacy, and the latest industry news.We are not doctors. Nothing in this video should be considered medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.
